|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002199,
umls-concept:C0017262,
umls-concept:C0041361,
umls-concept:C0087111,
umls-concept:C0165032,
umls-concept:C0185117,
umls-concept:C0205263,
umls-concept:C0205314,
umls-concept:C0679622,
umls-concept:C1423717,
umls-concept:C2911684
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2004-8-6
|
|
pubmed:abstractText |
Imiquimod represents a synthetic local immune response modifier that has demonstrated efficacy in clearing basal cell carcinoma. Via interaction with Toll-like receptor 7 on immune cells, imiquimod induces local production of cytokines, such as interferon (IFN)-alpha.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Aminoquinolines,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cell Surface,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Opioid,
http://linkedlifedata.com/resource/pubmed/chemical/TLR7 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptor 7,
http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptors,
http://linkedlifedata.com/resource/pubmed/chemical/imiquimod,
http://linkedlifedata.com/resource/pubmed/chemical/methionine-enkephalin receptor
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4959-70
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15297396-Adjuvants, Immunologic,
pubmed-meshheading:15297396-Aminoquinolines,
pubmed-meshheading:15297396-Antigens, Neoplasm,
pubmed-meshheading:15297396-Antineoplastic Agents,
pubmed-meshheading:15297396-Carcinoma, Basal Cell,
pubmed-meshheading:15297396-Cell Line, Tumor,
pubmed-meshheading:15297396-Cell Survival,
pubmed-meshheading:15297396-Disease-Free Survival,
pubmed-meshheading:15297396-Gene Expression Profiling,
pubmed-meshheading:15297396-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:15297396-Humans,
pubmed-meshheading:15297396-Immunoblotting,
pubmed-meshheading:15297396-Immunohistochemistry,
pubmed-meshheading:15297396-Interferon-alpha,
pubmed-meshheading:15297396-Membrane Glycoproteins,
pubmed-meshheading:15297396-Multigene Family,
pubmed-meshheading:15297396-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:15297396-Receptors, Cell Surface,
pubmed-meshheading:15297396-Receptors, Opioid,
pubmed-meshheading:15297396-Recurrence,
pubmed-meshheading:15297396-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:15297396-Toll-Like Receptor 7,
pubmed-meshheading:15297396-Toll-Like Receptors,
pubmed-meshheading:15297396-Treatment Outcome,
pubmed-meshheading:15297396-Up-Regulation
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?
|
|
pubmed:affiliation |
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
